Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Sponsor: Huahui Health
Summary
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Official title: A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)
Key Details
Gender
All
Age Range
12 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-04-22
Completion Date
2030-01-29
Last Updated
2026-08-24
Healthy Volunteers
No
Conditions
Interventions
Libevitug 20 mg/kg
Route of administration: intravenous infusion
Libevitug 10 mg/kg
Route of administration: intravenous infusion
Delayed treatment with libevitug
Route of administration: intravenous infusion
Locations (7)
Site 201
Garden Grove, California, United States
Site 101
Changchun, Jilin, China
Site 104
Kashgar, Xinjiang Uygur Autonomous Region, China
Site 103
Ürümqi, Xinjiang Uygur Autonomous Region, China
Site 303
Rawalpindi, Punjab Province, Pakistan
Site 301
Karachi, Sindh, Pakistan
Site 302
Karachi, Sindh, Pakistan